ENDRA Life Sciences
NDRA
9 hedge funds and large institutions have $1.89M invested in ENDRA Life Sciences in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 1 increasing their positions, 1 reducing their positions, and 1 closing their positions.
100% more first-time investments, than exits
New positions opened: 2 | Existing positions closed: 1
13% more funds holding
Funds holding: 8 → 9 (+1)
2% more capital invested
Capital invested by funds: $1.86M → $1.89M (+$28K)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$73K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$73K |
| 3 |
VF
Virtu Financial
New York
|
+$73K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SWM
SeaCrest Wealth Management
Purchase,
New York
|
-$146K |
| 2 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$94K |
| 3 |
PFGIA
Patriot Financial Group Insurance Agency
Westborough,
Massachusetts
|
-$5K |
NDRA Hedge Fund Activity: Q1 2019 in Review
9 of the 4,621 institutional investors tracked by Wall St. Rank reported a position in ENDRA Life Sciences (NDRA) for Q1 2019, worth a combined $1.89M — up 1.5% from $1.86M a quarter earlier.
Buyers outnumbered sellers: 2 funds opened new NDRA positions and 1 closed out — a net gain of 1 holder — while 1 added to existing stakes and 1 trimmed.
The largest buyer was Citadel Advisors, opening a new position worth an estimated $73K. The largest seller was SeaCrest Wealth Management, cutting an estimated $146K.
- 9 institutional investors held ENDRA Life Sciences (NDRA) as of Q1 2019, up from 8 in Q4 2018.
- Funds reported $1.89M of ENDRA Life Sciences stock for Q1 2019, up 1.5% quarter-over-quarter.
- 2 funds opened new ENDRA Life Sciences positions in Q1 2019 and 1 closed out, a net change of +1 holder.
- The largest ENDRA Life Sciences buyer in Q1 2019 was Citadel Advisors, an estimated $73K added.
- The largest ENDRA Life Sciences seller in Q1 2019 was SeaCrest Wealth Management, an estimated $146K sold.
Based on aggregated 13F filings for Q1 2019.